Cavium should be bought on any weakness after results, says Oppenheimer Oppenheimer expects Cavium to report stronger than expected Q1 results, but notes that the stock has dropped following modest beat and raise results in the past. The firm recommends buying the stock on any weakness after the results, as it expects the company's revenue to rise significantly in 2H14. The firm reiterates a $48 price target and Outperform rating on the shares.
News For CAVM From The Last 14 Days
Check below for free stories on CAVM the last two weeks.